Clinical Diagnostics

Blogs

DeciBio Analytics Launches 2021 DxBooks Databases

DeciBio Analytics has launched three 2021 DxBooks databases, covering U.S. labs’ testing behaviors in the areas of oncology biomarkers, infectious disease diagnostics, and SARS-CoV-2 testing. These databases, purchased in 2019

Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care

At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine.  To this end, we track this space closely, especially the field of precision oncology,

DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health

  DeciBio had the pleasure of interviewing Canexia Health’s SVP of Business Development, Brady Davis. We interviewed Brady to understand how Canexia Health and Project ACTT (Access to Testing and

Collaborative, Decentralized Research Drives Liquid Biopsy Advances – AGBT 2020

  For AGBT 2020, we analyzed collaboration networks within liquid biopsy publications to understand the landscape. We analyzed ~2,600 liquid biopsy publications 1, indexing ~1,300 affiliations and ~15,000 authors in 60

Supplying the COVID Demand — How Dx Behemoths and Tele-Diagnostics Entrants Aim to Close the Gap

  As more COVID-19 diagnostics win FDA emergency use authorization, weekly commercial production capacity is expected to hit 6.5M+ tests; telehealth providers attempt to jump into the fray, but are

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light

How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December

Going Viral: What the COVID-19 Outbreak Teaches Us About the Evolution of the Biotech Industry

  The novel coronavirus (COVID-19) outbreak has been a huge topic of concern across the globe as infection and death tolls continue to grow daily. However, it’s inarguable that the

Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.